文献速递白血病

阿扎胞苷联合或不联合度伐利尤单抗一线治疗老年急性髓系白血病的随机2期试验

A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML.
PubMed 文献 · Blood Adv · 2022-01-01

该2期研究将≥65岁急性髓系白血病患者随机分配至阿扎胞苷联合度伐利尤单抗组(A组,n=64)或单用阿扎胞苷组(B组,n=65),两组总缓解率相似(A组31.3% vs B组35.4%),总生存期(A组13.0个月 vs B组14.4个月)和缓解持续时间(A组24.6周 vs B组51.7周,P=.0765)亦相似,联合治疗未改善临床疗效。

要点

  • A组总缓解率31.3% vs B组35.4%,两组相似。
  • A组总生存期13.0个月 vs B组14.4个月,两组相似。
  • A组缓解持续时间24.6周 vs B组51.7周,P=.0765。

核心结论

  • 在老年急性髓系白血病患者中,度伐利尤单抗联合阿扎胞苷一线治疗可行,但与单用阿扎胞苷相比未改善临床疗效。

研究设计与样本

  • 随机2期研究,纳入≥65岁急性髓系白血病患者,随机分配至阿扎胞苷75 mg/m2第1至7天联合度伐利尤单抗1500 mg第1天每4周(A组,n=64)或不联合度伐利尤单抗(B组,n=65)的一线治疗。

主要发现

  • 总缓解率(完全缓解+血液学恢复不完全的完全缓解)A组31.3% vs B组35.4%,两组相似。
  • 总生存期A组13.0个月 vs B组14.4个月,两组相似。
  • 缓解持续时间A组24.6周 vs B组51.7周,P=.0765。
  • 联合治疗未出现新的安全性信号;最常见治疗中出现的不良事件为便秘(A组57.8% vs B组53.2%)和血小板减少(A组42.2% vs B组45.2%)。
  • DNA甲基化、突变状态和PD-L1表达与治疗缓解无关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Evidence suggests that combining immunotherapy with hypomethylating agents may enhance antitumor activity. This phase 2 study investigated the activity and safety of durvalumab, a programmed death-ligand 1 (PD-L1) inhibitor, combined with azacitidine for patients aged ≥65 years with acute myeloid leukemia (AML), including analyses to identify biomarkers of treatment response. Patients were randomized to first-line therapy with azacitidine 75 mg/m2 on days 1 through 7 with (Arm A, n = 64) or without (Arm B, n = 65) durvalumab 1500 mg on day 1 every 4 weeks. Overall response rate (complete response [CR] + CR with incomplete blood recovery) was similar in both arms (Arm A, 31.3%; Arm B, 35.4%), as were overall survival (Arm A, 13.0 months; Arm B, 14.4 months) and duration of response (Arm A, 24.6 weeks; Arm B, 51.7 weeks; P = .0765). No new safety signals emerged with combination treatment. The most frequently reported treatment-emergent adverse events were constipation (Arm A, 57.8%; Arm B, 53.2%) and thrombocytopenia (Arm A, 42.2%; Arm B, 45.2%). DNA methylation, mutational status, and PD-L1 expression were not associated with response to treatment. In this study, first-line combination therapy with durvalumab and azacitidine in older patients with AML was feasible but did not improve clinical efficacy compared with azacitidine alone. ClinicalTrials.gov: NCT02775903.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Zeidan AM, Boss I, Beach CL, et al. A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML. Blood Adv. 2022. PMID: 34933333. doi:10.1182/bloodadvances.2021006138

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。